{"title":"医药创新的革命:揭示中国内生知识溢出的影响。","authors":"Zhuolin Li, Lin Guo, Ying Ping","doi":"10.1371/journal.pone.0307171","DOIUrl":null,"url":null,"abstract":"<p><p>Modern medical technology innovation is a critical safeguard for human health, while a significant number of developing nations are confronted with the challenge of biopharmaceutical technological advancement. To investigate the possible routes of technological advancement, we investigated the impact of the endogenous knowledge spillover effect on firm innovation endeavors. Our research involves a theoretical two-stage R&D game model that is built around the characteristics of pharmaceutical organizations. Theoretical studies elucidated the impact as well as the probable mechanism of the spillover effect. To verify the theoretical study, we conducted econometric analysis using data from the pharmaceutical sector of Chinese enterprise listed on the A-share market. The study's findings indicate that endogenous knowledge spillovers impede organizations' innovation endeavors. This phenomenon may be attributed to the existence of the patent race paradigm and high concentration of enterprises' R&D endeavors in specific areas. Additional examination of heterogeneity demonstrates that private firms, small and medium-sized enterprises (SMEs), and non-high-tech enterprises experience a larger adverse impact from the spillover effect. Hence, we suggest implementing \"loser's subsidies\", reallocating R&D resources, and making modifications to competition policies as measures to enhance the innovation performance of biopharmaceutical markets. These policies will facilitate the technical advancement of medicines in developing nations.</p>","PeriodicalId":20189,"journal":{"name":"PLoS ONE","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414994/pdf/","citationCount":"0","resultStr":"{\"title\":\"Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China.\",\"authors\":\"Zhuolin Li, Lin Guo, Ying Ping\",\"doi\":\"10.1371/journal.pone.0307171\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Modern medical technology innovation is a critical safeguard for human health, while a significant number of developing nations are confronted with the challenge of biopharmaceutical technological advancement. To investigate the possible routes of technological advancement, we investigated the impact of the endogenous knowledge spillover effect on firm innovation endeavors. Our research involves a theoretical two-stage R&D game model that is built around the characteristics of pharmaceutical organizations. Theoretical studies elucidated the impact as well as the probable mechanism of the spillover effect. To verify the theoretical study, we conducted econometric analysis using data from the pharmaceutical sector of Chinese enterprise listed on the A-share market. The study's findings indicate that endogenous knowledge spillovers impede organizations' innovation endeavors. This phenomenon may be attributed to the existence of the patent race paradigm and high concentration of enterprises' R&D endeavors in specific areas. Additional examination of heterogeneity demonstrates that private firms, small and medium-sized enterprises (SMEs), and non-high-tech enterprises experience a larger adverse impact from the spillover effect. Hence, we suggest implementing \\\"loser's subsidies\\\", reallocating R&D resources, and making modifications to competition policies as measures to enhance the innovation performance of biopharmaceutical markets. These policies will facilitate the technical advancement of medicines in developing nations.</p>\",\"PeriodicalId\":20189,\"journal\":{\"name\":\"PLoS ONE\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414994/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PLoS ONE\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1371/journal.pone.0307171\",\"RegionNum\":3,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS ONE","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1371/journal.pone.0307171","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
现代医学技术创新是人类健康的重要保障,而大量发展中国家正面临着生物制药技术进步的挑战。为了探究技术进步的可能路径,我们研究了内生知识溢出效应对企业创新努力的影响。我们的研究涉及一个围绕制药企业特点建立的两阶段研发博弈理论模型。理论研究阐明了溢出效应的影响和可能机制。为了验证理论研究,我们利用中国 A 股上市企业医药行业的数据进行了计量分析。研究结果表明,内生知识溢出会阻碍组织的创新努力。这种现象可能是由于专利竞赛范式的存在和企业研发活动高度集中于特定领域所致。对异质性的进一步研究表明,私营企业、中小型企业和非高科技企业受到的溢出效应的不利影响更大。因此,我们建议实施 "输家补贴"、重新分配研发资源、修改竞争政策等措施来提高生物制药市场的创新绩效。这些政策将促进发展中国家药品技术的进步。
Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China.
Modern medical technology innovation is a critical safeguard for human health, while a significant number of developing nations are confronted with the challenge of biopharmaceutical technological advancement. To investigate the possible routes of technological advancement, we investigated the impact of the endogenous knowledge spillover effect on firm innovation endeavors. Our research involves a theoretical two-stage R&D game model that is built around the characteristics of pharmaceutical organizations. Theoretical studies elucidated the impact as well as the probable mechanism of the spillover effect. To verify the theoretical study, we conducted econometric analysis using data from the pharmaceutical sector of Chinese enterprise listed on the A-share market. The study's findings indicate that endogenous knowledge spillovers impede organizations' innovation endeavors. This phenomenon may be attributed to the existence of the patent race paradigm and high concentration of enterprises' R&D endeavors in specific areas. Additional examination of heterogeneity demonstrates that private firms, small and medium-sized enterprises (SMEs), and non-high-tech enterprises experience a larger adverse impact from the spillover effect. Hence, we suggest implementing "loser's subsidies", reallocating R&D resources, and making modifications to competition policies as measures to enhance the innovation performance of biopharmaceutical markets. These policies will facilitate the technical advancement of medicines in developing nations.
期刊介绍:
PLOS ONE is an international, peer-reviewed, open-access, online publication. PLOS ONE welcomes reports on primary research from any scientific discipline. It provides:
* Open-access—freely accessible online, authors retain copyright
* Fast publication times
* Peer review by expert, practicing researchers
* Post-publication tools to indicate quality and impact
* Community-based dialogue on articles
* Worldwide media coverage